ESR1 and breast carcinoma: TNBC cell lines BT549, Hs578T (Supplementary Fig. 3a, b), and SUM-149 breast cancer cells treated with dinaciclib also exhibited upregulation of ERα expression and reduction of phospho-CDK2 and pT416-EZH2 (Fig. 2f and Supplementary Fig. 3c).